Recently, immune checkpoint blockage through targeting programmed death-ligand 1 (PD-L1) and by its receptor programmed death-1 (PD-1), has changed the treatment paradigm for lung cancer patients, especially for those harboring a KRAS mutation [4]. The gene discussed is KRAS; the disease is lung carcinoma.